Nicholas Corcoran Sells 3,222 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Nicholas Corcoran sold 3,222 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $129.91, for a total transaction of $418,570.02. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $2,741,750.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

TransMedics Group Stock Up 1.2 %

TMDX opened at $128.77 on Friday. The stock’s 50 day moving average price is $89.25 and its 200 day moving average price is $79.26. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The stock has a market cap of $4.24 billion, a P/E ratio of -378.74 and a beta of 1.87. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $132.96.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period last year, the company earned ($0.08) earnings per share. As a group, research analysts predict that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC raised its holdings in TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares in the last quarter. Eventide Asset Management LLC raised its stake in shares of TransMedics Group by 1,271.7% in the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after buying an additional 857,895 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of TransMedics Group in the fourth quarter valued at $35,804,000. Wasatch Advisors LP bought a new position in TransMedics Group during the first quarter valued at about $32,162,000. Finally, Bank of New York Mellon Corp grew its holdings in TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after acquiring an additional 363,012 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TMDX shares. TD Cowen lifted their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Oppenheimer lifted their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Morgan Stanley increased their price target on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price objective on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group upped their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $119.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.